Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount

2024-05-15

抗体药物偶联物临床结果临床1期

Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California biotech said Tuesday afternoon that it is dropping its lead oncology asset, as well as staging an executive team revamp and slashing its employee count in half. Bolt will cease development of an immune-stimulating antibody conjugate (ISAC), dubbed trastuzumab imbotolimod or BDC-1001, after the company found it was unlikely to meet a predefined success criteria. The candidate was in a Phase 1/2 trial in solid tumors, but had lackluster results in 2021. BDC-1001 comprises a HER2-targeting biosimilar of Herceptin conjugated with a TLR7/8 agonist.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构